StrataGraft manufacturing facility unveiled

Mallinckrodt Pharmaceuticals, parent company of Madison-based Stratatech, celebrated the completion of its expanded operations and Madison manufacturing facility for the investigational StrataGraft regenerative skin tissue with a ribbon cutting ceremony Wednesday, April 24. The 35,000-square-foot facility provides the necessary capacity to develop and manufacture StrataGraft regenerative skin tissue for both clinical trials and commercial availability, if approved by the FDA. The state-of-the-art facility offers a fully sterile environment for manufacturing, with controlled temperature, humidity, and constant carbon dioxide levels. It also features biosafety cabinets, incubators, freezers, a quality control lab, and a warehouse for shipping. (For information on getting your event featured in the IB Gallery, email